-
1
-
-
5144229259
-
EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)
-
Madersbacher S., Alivizatos G., Nordling J., Sanz Rioja C., Emberton M., and de la Rosette J.J.M.C.H. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46 (2004) 547-554
-
(2004)
Eur Urol
, vol.46
, pp. 547-554
-
-
Madersbacher, S.1
Alivizatos, G.2
Nordling, J.3
Sanz Rioja, C.4
Emberton, M.5
de la Rosette, J.J.M.C.H.6
-
2
-
-
0038672692
-
-
American Urological Association Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003;170:530-47.
-
American Urological Association Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003;170:530-47.
-
-
-
-
3
-
-
29144516614
-
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater
-
Kaplan S.A., McConnell J.D., Roehrborn C.G., et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175 (2006) 217-220
-
(2006)
J Urol
, vol.175
, pp. 217-220
-
-
Kaplan, S.A.1
McConnell, J.D.2
Roehrborn, C.G.3
-
4
-
-
34848860581
-
Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design
-
Siami P., Roehrborn C.G., Barkin J., et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 28 (2007) 770-779
-
(2007)
Contemp Clin Trials
, vol.28
, pp. 770-779
-
-
Siami, P.1
Roehrborn, C.G.2
Barkin, J.3
-
5
-
-
38849201263
-
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study
-
Roehrborn C.G., Siami P., Barkin J., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179 (2008) 616-621
-
(2008)
J Urol
, vol.179
, pp. 616-621
-
-
Roehrborn, C.G.1
Siami, P.2
Barkin, J.3
-
6
-
-
9444268678
-
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
-
Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335 (1996) 533-539
-
(1996)
N Engl J Med
, vol.335
, pp. 533-539
-
-
Lepor, H.1
Williford, W.O.2
Barry, M.J.3
-
7
-
-
0037253614
-
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial
-
Kirby R.S., Roehrborn C., Boyle P., et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61 (2003) 119-126
-
(2003)
Urology
, vol.61
, pp. 119-126
-
-
Kirby, R.S.1
Roehrborn, C.2
Boyle, P.3
-
8
-
-
0031718686
-
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia
-
Debruyne F.M., Jardin A., Colloi D., et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 34 (1998) 169-175
-
(1998)
Eur Urol
, vol.34
, pp. 169-175
-
-
Debruyne, F.M.1
Jardin, A.2
Colloi, D.3
-
9
-
-
0347882750
-
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
-
McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
-
(2003)
N Engl J Med
, vol.349
, pp. 2387-2398
-
-
McConnell, J.D.1
Roehrborn, C.G.2
Bautista, O.M.3
-
10
-
-
34447123669
-
Efficacy of dutasteride and finasteride for the treatment of benign prostate hyperplasia: results of the 1-year enlarged prostate international comparator study (EPICS) [abstract]
-
Gilling P.J., Jacobi G., Tammela T.L., and van Erps P. Efficacy of dutasteride and finasteride for the treatment of benign prostate hyperplasia: results of the 1-year enlarged prostate international comparator study (EPICS) [abstract]. BJU Int 95 (2005) 12
-
(2005)
BJU Int
, vol.95
, pp. 12
-
-
Gilling, P.J.1
Jacobi, G.2
Tammela, T.L.3
van Erps, P.4
-
11
-
-
0037385072
-
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial
-
Bautista O.M., Kusek J.W., Nyberg L.M., et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 24 (2003) 224-243
-
(2003)
Control Clin Trials
, vol.24
, pp. 224-243
-
-
Bautista, O.M.1
Kusek, J.W.2
Nyberg, L.M.3
-
12
-
-
40849120933
-
Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
-
Barendrecht M.M., Abrams P., Schumacher H., de la Rosette J.J., and Michel M.C. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?. Neurourol Urodyn 27 (2008) 226-230
-
(2008)
Neurourol Urodyn
, vol.27
, pp. 226-230
-
-
Barendrecht, M.M.1
Abrams, P.2
Schumacher, H.3
de la Rosette, J.J.4
Michel, M.C.5
-
13
-
-
0141572168
-
Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride
-
Barkin J., Guimarães M., Jacobi G., Pushkar D., Taylor S., and van Vierssen Trip O.B. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 44 (2003) 461-466
-
(2003)
Eur Urol
, vol.44
, pp. 461-466
-
-
Barkin, J.1
Guimarães, M.2
Jacobi, G.3
Pushkar, D.4
Taylor, S.5
van Vierssen Trip, O.B.6
-
14
-
-
36348939350
-
Statistics in medicine-reporting of subgroup analyses in clinical trials
-
Wang R., Lagakos S.W., Ware J.H., Hunter D.J., and Drazen J.M. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 357 (2007) 2189-2194
-
(2007)
N Engl J Med
, vol.357
, pp. 2189-2194
-
-
Wang, R.1
Lagakos, S.W.2
Ware, J.H.3
Hunter, D.J.4
Drazen, J.M.5
|